Mucoadhesive carriers for oral drug delivery
Among the various dosage forms, oral medicine has extensive benefits including ease of
administration and patients' compliance, over injectable, suppositories, ocular and nasal …
administration and patients' compliance, over injectable, suppositories, ocular and nasal …
Natural polysaccharide-based nanodrug delivery systems for treatment of diabetes
A Qiu, Y Wang, G Zhang, H Wang - Polymers, 2022 - mdpi.com
In recent years, natural polysaccharides have been considered as the ideal candidates for
novel drug delivery systems because of their good biocompatibility, biodegradation, low …
novel drug delivery systems because of their good biocompatibility, biodegradation, low …
Coating of betanin and carvone Co-loaded nanoliposomes with synthesized cationic inulin: A strategy for enhancing the stability and bioavailability
Betanin (BET) and carvone (CAR) as antioxidant and antibacterial compounds were co-
loaded in the coated nanoliposomes (NLPs) with cationic inulin to improve their stability and …
loaded in the coated nanoliposomes (NLPs) with cationic inulin to improve their stability and …
Polyelectrolyte multilayered capsules as biomedical tools
A Mateos-Maroto, L Fernández-Peña… - Polymers, 2022 - mdpi.com
Polyelectrolyte multilayered capsules (PEMUCs) obtained using the Layer-by-Layer (LbL)
method have become powerful tools for different biomedical applications, which include …
method have become powerful tools for different biomedical applications, which include …
Targeted delivery of 5-fluorouracil, miR-532-3p, and si-KRAS to the colorectal tumor using layer-by-layer liposomes
M Shahidi, O Abazari, P Dayati… - … in Bioengineering and …, 2022 - frontiersin.org
Co-delivery of siRNA or miRNA with chemotherapeutic drugs into tumor sites is an attractive
synergetic strategy for treating colorectal cancer (CRC) due to their complementary …
synergetic strategy for treating colorectal cancer (CRC) due to their complementary …
Combating hematopoietic and hepatocellular abnormalities resulting from administration of cisplatin: role of liver targeted glycyrrhetinic acid nanoliposomes loaded …
The effectiveness of cisplatin in cancer treatment renders its use vital to clinicians. However,
the accompanying side effects as cachexia, emesis and liver damage necessitate the use of …
the accompanying side effects as cachexia, emesis and liver damage necessitate the use of …
Exploring ex vivo peptideolysis of thymopentin and lipid-based nanocarriers towards oral formulations
The oral delivery of medicines is the most popular route of administration for patients.
However, thymopentin (TP5) is only available in the market in forms for parenteral …
However, thymopentin (TP5) is only available in the market in forms for parenteral …
Current advances and future prospects in production of recombinant insulin and other proteins to treat diabetes mellitus
S Bhoria, J Yadav, H Yadav, D Chaudhary… - Biotechnology …, 2022 - Springer
Diabetes mellitus is the most prevalent deadly disease caused by the destruction and
dysfunction of pancreatic β cells that consequentially increased blood glucose levels. The …
dysfunction of pancreatic β cells that consequentially increased blood glucose levels. The …
Glucose-activatable insulin delivery with charge-conversional polyelectrolyte multilayers for diabetes care
Y Yang, X Wang, X Yuan, Q Zhu, S Chen… - … in Bioengineering and …, 2022 - frontiersin.org
One of the most effective treatments for diabetes is to design a glucose-regulated insulin
(INS) delivery system that could adjust the INS release time and rate to reduce diabetes …
(INS) delivery system that could adjust the INS release time and rate to reduce diabetes …
Diabetic retinopathy treatments based on nanotechnology
M Montoya-Álvarez, J Gonzalez-Perez… - ScienceOpen …, 2022 - scienceopen.com
Diabetes is a metabolic disorder characterized by a high level of glucose in the blood.
Diabetes is projected to affect 366 million people by 2030, and the prevalence of diabetic …
Diabetes is projected to affect 366 million people by 2030, and the prevalence of diabetic …